The CEO and founder of Turing Pharmaceuticals, Martin Shkreli, has enlisted the help of media professionals to deal with the fallout from his very public price hike of a newly-purchase AIDS and cancer drug. He’s a man in dire need of a rebrand. After being pilloried on social and mainstream media for bumping the price […]
The CEO and founder of Turing Pharmaceuticals, Martin Shkreli, has enlisted the help of media professionals to deal with the fallout from his very public price hike of a newly-purchase AIDS and cancer drug.
He’s a man in dire need of a rebrand. After being pilloried on social and mainstream media for bumping the price of pyrimethamine (Daraprim) from $13.50 to $750 a tablet, Shkreli eventually announced the company would be lowering the cost an undisclosed amount. But that doesn’t seem to be enough. Excerpts from an October 6 interview with Shkreli were published by Reuters, from a leaked private quarterly report by Activist Shorts Research.
“Yes, we have a plan. Very expensive, well articulated,” Shkreli said on the topic of salvaging his public image. “Every media advisor is on our payroll.” However he told Activist Shorts Research founder Adam Kommel that it wasn’t going to be a complete overhaul. “Being true and authentic is important,” he told Kommel. “If you react to how people act to you, you end up being a ghost of yourself, and that’s one of the worst things that could happen. I’m not sure it’s going to dramatically change the way I act.”
Original Reuters Story HERE
